A Phase II Study of Rapamycin (Rapamune, Sirolimus) and Trastuzumab (Herceptin) for Patients With HER-2 Receptor Positive Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Sirolimus (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Aug 2016 Status changed from recruiting to completed.
- 16 Jun 2009 Primary endpoint identified as (clinical activity) and trial phase changed from I/II to II as reported by ClinicalTrials.gov.